In the present study, we show that lapatinib (2–20 μM) activates the Keap1-Nrf2 pathway in HepG2 cells, a hepatocellular carcinoma-derived cell line, in a concentration-dependent manner upon 24 h of treatment. Here, KEAP1 is linked to hepatocellular carcinoma.